Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tempus AI Q3 2026 Results: Net Loss of $14.9M, Loss Narrows

Tempus AI reported total net revenue of $411.5 million for the third quarter of 2026, a 23% increase year-over-year, driven by growth in both Diagnostics and Data and Applications segments. The company significantly narrowed its net loss to $14.9 million compared to $80.0 million in the prior year period, aided by a substantial $108.9 million gain on marketable equity securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue411.5334.2
Profit before tax-12.4-81.2
Net income-14.9-80.0
EPS (diluted, $ a share)$-0.08$-0.46

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+23.1%
Operating margin-13.8%
Source

10-Q filed with the SEC, NASDAQ: TEM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tempus AI, Inc.: key numbers

Share price
$64.76Close, Nov 16
Sector
Technology
Industry
Services-Computer Programming, Data Processing, Etc.SIC 7370

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tempus AI, Inc.

All →
4:30 PM ET Form 4
Insider Selling

Tempus AI Director David R. Epstein Sells $27.5K of Stock

David R. Epstein, Director, sold 370 shares of Tempus AI, Inc. at $74.29 a share, worth $27.5K in total on Nov 2, 2026. Shares held after the trade: 30,474 (-1.2%).

Value
$27.5K
Shares
370
Price
$74.29
Role
Director
Holding change
-1.2%
Trade date
Nov 2, 2026
7:00 AM ET 8-K
Financial Results

Tempus AI Financial Results

Tempus AI reported record Q3 2026 revenue of $411.5 million, a 23% year-over-year increase driven by strong growth in its Oncology and Data & Applications segments. The company narrowed its net loss to $14.9 million and raised its full-year 2026 revenue guidance to a range of $1.60 billion to $1.605 billion.

Term
Q3 2026

“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”

Eric Lefkofsky, founder and CEO of Tempus
4:15 PM ET Form 4
Insider Selling

Tempus AI CEO and Chairman Eric P. Lefkofsky Sells $17.6M of Stock

Eric P. Lefkofsky, CEO and Chairman, sold 250,000 shares of Tempus AI, Inc. at $67.36 to $72.31 a share (average $70.36) in 24 transactions, worth $17.6M in total on Oct 27, 2026. Shares held after the trade: 50,000 (-20.9%).

Value
$17.6M
Shares
250,000
Average price
$70.36
Role
CEO and Chairman
Holding change
-20.9%
Trade date
Oct 27, 2026
9:01 AM ET 8-K
Licensing Deal

Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M

Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.

Value
$192M
Counterparty
Bristol-Myers Squibb Company
Term
5 years
4:16 PM ET Form 4
Insider Selling

Tempus AI CEO and Chairman Eric P. Lefkofsky Sells $19.4M of Stock

Eric P. Lefkofsky, CEO and Chairman, sold 249,976 shares of Tempus AI, Inc. at $76.57 to $78.86 a share (average $77.47) in 15 transactions, worth $19.4M in total on Sep 22, 2026. Shares held after the trade: 804,246 (-0.5%).

Value
$19.4M
Shares
249,976
Average price
$77.47
Role
CEO and Chairman
Holding change
-0.5%
Trade date
Sep 22, 2026
9:15 PM ET Form 4
Insider Selling

Tempus AI EVP, CLO Andrew Polovin Sells $221K of Stock

Andrew Polovin, EVP, CLO, sold 2,951 shares of Tempus AI, Inc. at $75.00 a share, worth $221K in total on Sep 17, 2026. Shares held after the trade: 135,189 (-2.1%).

Value
$221K
Shares
2,951
Price
$75.00
Role
EVP, CLO
Holding change
-2.1%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.